摘要
运动性哮喘(支气管收缩或)折磨全世界数百万人。虽然通常自限性,它可以阻碍性能,减少活动量,因此它是诊断和治疗的重要条件。这种评价的目的是评估奈多罗米钠对运动诱发哮喘的单次剂量的预防效果。科克伦航空集团试验注册的临床对照试验注册,当前内容相关的文章,评论文章和教科书的参考文献目录进行随机试验奈多罗米单剂量比较安慰剂,以防止人们运动性哮喘> 6年年龄。作者和药品生产企业进行了接触更多的试验。试验质量评估和数据提取由两位研究者独立进行。作者进行联系时可能。二十试验被纳入。所有被评为具有良好的方法学质量。 Nedocromil inhibited bronchoconstriction in all age groups. The pooled weighted mean difference for the maximum percentage fall in forced expiratory volume in one second was 15.6%, (95% confidence interval (95% CI): 13.2-18.1) and for the peak expiratory flow was 15.0% (95% CI: 8.3-21.6). These differences are both statistically and clinically significant. After nedocromil the time to recover normal lung function was <10 min compared to >30 min with placebo. Nedocromil had a greater effect on people with a fall in lung function of >30% from baseline. There were no significant adverse effects reported with this short-term use. In conclusion, Nedocromil taken before exercise appears to reduce the severity and duration of exercise-induced bronchoconstriction. This effect appears to be more pronounced as severity increases.